ODAC Cautiously Backs Keytruda in Early Bladder Cancer

]]>(MedPage Today) -- SILVER SPRING, Md.--With some hesitation, an FDA advisory panel supported pembrolizumab (Keytruda) as a bladder-sparing option in high-risk, non-muscle-invasive bladder cancer (NMIBC) patients who don't respond to standard...